AVBP · ArriVent BioPharma, Inc.
$29.18
-0.84 (-2.80%)
At close · Aug 20
Market Cap
$1.44B
Shares
49.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.18
Open$29.73
Day$28.64–29.81
52W close$17.17–34.74
Avg vol 30d467K
Short int8.0M · 16.3% float · 13.9d
Short vol89%
Last earningsMay 11, 2026
DataJan 2024–Aug 2026
Filing10-Q · Aug 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+12%
above
Price vs 50-day avg
−8%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
68%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+27%
trailing
YTD return
+45%
this year
Relative strength
+16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $32 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.32% of float · ▲ +5.0% MoM · 13.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
158 holders — near 2-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
EPS growth
−69%
Y/Y
Balance sheet
$45.5M
net cash
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−24%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+12%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
68%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $32 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.32% of float · ▲ +5.0% MoM · 13.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
158 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $17
Now $29 · 68%
Range high $35
vs 200-day avg +12%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVBP
this stock
ArriVent BioPharma, Inc.
|
$1.44B | +45.0% | — | — | 16.3% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVBP | -2.7% | -7.5% | +27.0% | -2.2% | +45.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -0.8% | -10.8% | +15.9% | -4.2% | +33.2% |
Key facts
CIK
1868279
CUSIP
04272N102
13F (30d)
149 filings
148 filers
Visit website
Investor relations